New drug combo aims to shrink stomach cancer before surgery
NCT ID NCT07493382
First seen Mar 26, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This study tests whether adding Retlirafusp alfa to standard chemotherapy before and after surgery can improve outcomes for people with gastroesophageal junction cancer. About 30 adults with HER2-negative, CPS>5 tumors will receive 3 cycles of the drug combo, then surgery, then possibly more Retlirafusp alfa alone. The main goal is to see how many patients have no cancer left after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEJ ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.